Navigation Links
Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
Date:5/2/2008

d.

About Colorectal Cancer

Colorectal cancer is a worldwide public health problem, with more than 940,000 new cases diagnosed each year, resulting in approximately 500,000 deaths.(2) In the U.S., it is the third leading cause of cancer mortality, and in 2008, nearly 50,000 deaths will be attributed to this disease.(3) Its incidence rate is strongly correlated with age. Data from industrialized countries demonstrate that the incidence of colorectal cancer rises three-fold between the ages of 60 and 80 years.(4)

About Saladax

Saladax Biomedical is pioneering the development of novel, fast, and inexpensive immunoassays that will enable routine blood-level monitoring of anti-cancer drugs to become the standard-of-care in treating cancer patients. With Personalized Chemotherapy Management (PCM), oncologists will be able to adjust the administered dose based on each patient's individual drug level, leading to reduced toxicity, improved outcome and lower cancer care costs. Saladax is headquartered at the business incubator of the Ben Franklin Technology Partners (BFTP) of Northeastern Pennsylvania on the campus of Lehigh University in Bethlehem. The 5-FU PCM test will be available to U.S. clinicians later this year through a major reference laboratory.

(1) Proceedings from the American Society of Clinical Oncology - GI,

January 2008; Orlando, FL Abstract #429 & Abstract #431

(2) World Health Organization, "World Cancer Report." April 3, 2003,

http://www.who.int/mediacentre/news/releases/2003/pr27/en/ (April 22,

2008).

(3) American Cancer Society, "What are the Key Statistics for Colorectal Cancer?," March 5, 2008, http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_stati sti cs_for_
'/>"/>

SOURCE Saladax Biomedical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
2. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders
5. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
8. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... highlighted findings from a pre-clinical study published in ... Sciences ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ... anti-PD-L1 antibody (a checkpoint inhibitor), suppression of tumor ... be achieved when treating certain hematologic cancers and ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today ... operating loss (NOL) guidance and its cash guidance ending ... improved financial results were due in large part to ... received from its partners.  Isis, pro forma NOL of ... over its 2013 NOL of $40.2 million. On a ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 9, 2011 Vyatta , ... and cloud infrastructures, today announced that the Vyatta ... selected to provide HIPAA compliant network security for ... information technology to deploy scalable, collaborative healthcare networks ...
... AMBLER, Pa., Aug. 9, 2011 Allergy Technologies LLC, ... liners, is sponsoring a new bed bug research program at ... by the Company. This new endeavor will ... strategies relating to innovative bed bug treatment applications. The dramatic ...
Cached Medicine Technology:Vyatta Virtual Firewall Addresses HIPAA Compliance for Thrasys 2Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs 2
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Fredericton, NB (PRWEB) February 28, 2015 ... call center software suite for Asterisk, are pleased to ... the highly successful 5.7 and 5.8 versions of Q-Suite, ... as well as a number of new features to ... be Q2 2015. , Q-Suite 5.9 will add features ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Save the Children By Charles ... WESPORT, Conn., Oct. 24 The dramatic images,of wildfires ... on,children not only in the immediate area where the ... country who are watching the,destructive power of the flames ...
... Company Becomes First to Leverage Zagat,s, Expertise to Survey ... Rate Experiences Using ... Oct. 24 WellPoint, Inc., the,nation,s largest health benefits ... of a new online survey tool that will allow,consumers ...
... Pennsylvania has reversed the medical malpractice trend, ... said that Medical Care Availability and Reduction of ... since he took office and, as,a result of ... "Pennsylvania is a success story when it ...
... a novel,medical humidifier, was awarded a prestigious R&D ... PARI Innovative Manufacturers, a leading,manufacturer of nebulizers and ... gases are heated and humidified with the aim ... greater control,of patient comfort. The award, selected ...
... -- Combat physicians in war-torn areas like Iraq and ... require massive blood transfusions (MT), and thereby increase a ... the October issue of The Journal of the American ... of a combination of three variables -- assessed immediately ...
... induced in healthy volunteers, according to a study by ... Center for Medical Cannabis Research (CMCR.) However, the ... the placebo controlled study of 15 subjects, a low ... provided moderate pain relief, and a high dose increased ...
Cached Medicine News:Health News:How to Help Children Cope With the California Wildfires 2Health News:How to Help Children Cope With the California Wildfires 3Health News:How to Help Children Cope With the California Wildfires 4Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Early predictive model may be new 'weapon' against leading cause of death on battlefield 2Health News:Smoked cannabis proven effective in treating neuropathic pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: